Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 04/26 02:58:23 pm
217.65 CHF   -0.05%
01:14pBiosimilar worries takes shine off Roche's guidance hike
RE
08:46aRoche Lifts Outlook as 1Q Sales Rise Above Expectations -- Update
DJ
08:05aCorrection to Roche Article on 1Q Sales
DJ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/20/2018 04/23/2018 04/24/2018 04/25/2018 04/26/2018 Date
215.65(c) 217.6(c) 219.2(c) 217.75(c) 217.8 Last
1 825 021 3 617 172 1 696 826 1 371 842 688 590 Volume
-0.39% +0.90% +0.74% -0.66% +0.02% Change
More quotes
Financials (CHF)
Sales 2018 55 182 M
EBIT 2018 18 555 M
Net income 2018 11 868 M
Debt 2018 4 203 M
Yield 2018 3,97%
Sales 2019 57 010 M
EBIT 2019 19 233 M
Net income 2019 12 684 M
Finance 2019 251 M
Yield 2019 4,07%
P/E ratio 2018 15,26
P/E ratio 2019 14,54
EV / Sales2018 3,53x
EV / Sales2019 3,34x
Capitalization 191 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
04/25 | 12:42amPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
01:14pBiosimilar worries takes shine off Roche's guidance hike
RE
08:46aRoche Lifts Outlook as 1Q Sales Rise Above Expectations -- Update
DJ
08:05aCorrection to Roche Article on 1Q Sales
DJ
07:35aRoche Raises Outlook After 1Q Sales Increase
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/23ROCHE : New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions..
BU
04/18GSK flags pharma M&A ambitions by poaching Roche deal-maker
RE
04/18Shire faces criticism on CEO pay policy as crunch week looms
RE
04/17ROCHE : FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIB..
BU
04/16GENENTECH : to Present New Data at AAN Highlighting Extensive Research for OCREV..
BU
More news
Sector news : Pharmaceuticals - NEC
01:26pBRISTOL MYERS SQUIBB : Opdivo Drives Bristol-Myers Growth -- Earnings Review
DJ
01:20pSHIRE : Bid target Shire reports 6 percent rise in first-quarter earnings
RE
01:16pSHIRE PLC SHIRE PLC : 1st Quarter Results -8-
DJ
01:16pSHIRE PLC SHIRE PLC : 1st Quarter Results -7-
DJ
01:16pSHIRE PLC SHIRE PLC : 1st Quarter Results -6-
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
01:11pRoche Q1 sales up 5%, core earnings growth expected to be high single-digit
1
01:05pFoundation Medicine : New Liquid Biopsy Assay Granted Breakthrough Device Des.. 
09:56aI see Roche edged up its sales hopes for the FY. Solid and cheap stock IMO....
1
09:52aGood morning. The is coming up just after 9am this morning and today Ryan wi..
3
09:44a#Roche lifts 2018 guidance as new drugs offset #biosimilars
1
More tweets
Qtime:218
News from SeekingAlpha
07:11aRoche Q1 sales up 5%, core earnings growth expected to be high single-digit 
04/25BIOGEN : Down Too Far, Too Fast? 
04/25PROTHENA : A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout T.. 
04/25Late-stage study underway for AVXS-101 in pre-symptomatic spinal muscular atr.. 
04/24Prothena Ends Up With Two Trial Failures, Becomes A Great Short Opportunity 
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 258  CHF
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-11.66%193 904
JOHNSON & JOHNSON-9.28%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
MERCK AND COMPANY5.97%161 967
AMGEN-1.13%114 902